Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Diclofenac conjugated sodium hyaluronate
Therapeutic Area : Musculoskeletal
Study Phase : Phase III
Sponsor : Eisai
Deal Size : Undisclosed
Deal Type : Agreement
Eisai and Seikagaku Enter into Agreement for the Co-development and Marketing Alliance of SI-613
Details : The companies will jointly develop SI-613 in China for knee osteoarthritis. After obtaining approval, Seikagaku will supply products to Eisai, and Eisai will be responsible for distribution.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
April 01, 2020
Lead Product(s) : Diclofenac conjugated sodium hyaluronate
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase III
Sponsor : Eisai
Deal Size : Undisclosed
Deal Type : Agreement
LOOKING FOR A SUPPLIER?
Reset All
